What is AUPH's current stock price?

AUPH (Aurinia Pharmaceuticals Inc.) is currently trading at $15.22 with a market cap of $1.96B.

What sector is Aurinia Pharmaceuticals Inc. in?

Aurinia Pharmaceuticals Inc. (AUPH) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AUPH a good stock to buy?

Analysts have a Hold consensus on AUPH with a price target of $16.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AUPH Aurinia Pharmaceuticals Inc.

Healthcare

$15.22-1.49%ClosedMarket Cap: $1.96B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

7.30

PEG

0.00

P/B

3.55

P/S

6.56

EV/EBITDA

12.27

DCF Value

$-48.57

FCF Yield

8.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

89.7%

Operating Margin

41.7%

Net Margin

100.0%

ROE

64.5%

ROA

41.2%

ROIC

19.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$77.7M	$34.4M	$—
Q4 null	$77.1M	$210.8M	$—
FY null	$283.1M	$287.2M	$—
Q3 null	$73.5M	$31.6M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$16.00

Target (Median)

$16.00

Target Range

$16.00 - $16.00

0 Strong Buy4 Buy3 Hold0 Sell0 Strong Sell

Leerink PartnersMarket Perform

2025-12-03

JefferiesBuy

2025-11-07

RBC CapitalSector Perform

2025-11-05

RBC CapitalOutperform

2025-08-01

Trading Activity

Insider Trades

View All

Robertson Stephen P.officer: Chief Legal Officer

SellWed May 20

Hearne Michael Sofficer: Chief Financial Officer

SellWed May 20

Hearne Michael Sofficer: Chief Financial Officer

SellWed May 20

Cole Ryanofficer: Chief Operating Officer

SellWed May 20

Cole Ryanofficer: Chief Operating Officer

SellWed May 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.45

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Peers